The current study was designed to evaluate the correlation between SphK expression level and the microvascular density of ovarian cancer tissue, and to investigate the in vitro and in vivo effects of targeting SphK or S1PRs with specific antagonists or siRNAs on ovarian cancer angiogenesis. Here, SPHK1 is linked to ovarian carcinoma.